Exelixis, Inc.

Development of pharmaceutical and agricultural products

Exelixis (NASDAQ: EXEL) is a genomics-based drug discovery company with focus on cancer and other proliferative diseases. Founded and incorporated in 1994, Exelixis, Inc. has evolved from a privately financed genetics company into a publicly traded biotechnology company with interests in both the pharmaceutical and agricultural industries. Exelixis also owns Artemis Pharmaceuticals in Cologne, Germany.

George A. Scangos, Ph.D., President, CEO
Frank Karbe, Senior VP, CFO
Michael Morrissey, Ph.D., President of R&D
Peter Lamb, Ph.D., Senior VP of Discovery Research and SCO
Lupe M. Rivera, Senior VP of Operations
Gisela M. Schwab, M.D., Senior VP and CMO
Pamela A. Simonton, Senior VP of Patents and Licensing
D. Ry Wagner, Ph.D., VP of Research

Stelios Papadopoulos, Ph.D., Chairman
Charles Cohen, Ph.D.
Carl B. Feldbaum
Alan M. Garber, M.D., Ph.D.
Vincent Marchesi, M.D., Ph.D.
Frank McCormick, Ph.D.
George Poste, Ph.D.
George A. Scangos, Ph.D.
Lance Willsey, M.D.
Jack L. Wyszomierski

Jose Baselga, Dr.
Ronald M. Evans, Ph.D.
Frank McCormick, Ph.D.
Charles Sawyers, Ph.D., M.D.

210 East Grand Avenue
So. San Francisco, CA 94080
USA
Phone: +1-650 837-7000
Fax: +1-650-837-8300

Exelixis has a multidisciplinary, integrated research and development platform for drug research, discovery and clinical development. Using this gene-to-drug platform, the company is able to identify novel targets and develop proprietary compounds. The biology-based research platform focuses on invertebrate and vertebrate genetics and comparative genomics, informatics, cell biology and protein production for high throughput target identification and validation. Exelixis’ discovery platform occupies combinatorial chemistry, high throughput screening and new lead discovery, structural biology, medicinal chemistry, pharmacology and ADME/toxicology in order to rapidly identify and optimise lead compounds. In the field of agriculure Exelixis is developing new products for crop protection and plant biotechnology.

Phase 3 trial for XL119 began in June of 2004 as a treatment for bile duct tumours. XL784 has completed a Phase 1 trial using in renal disease. A Phase 1 clinical trial for XL647, a multiple potential anticancer compounds, commenced in June of 2004.
Exelixis started a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of XL820, a small molecule anticancer compound, in summer 2005.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.